These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 25647729)

  • 21. Design of tenofovir-UC781 combination microbicide vaginal gels.
    Kiser PF; Mahalingam A; Fabian J; Smith E; Damian FR; Peters JJ; Katz DF; Elgendy H; Clark MR; Friend DR
    J Pharm Sci; 2012 May; 101(5):1852-64. PubMed ID: 22359356
    [TBL] [Abstract][Full Text] [Related]  

  • 22. One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidates.
    Denton PW; Othieno F; Martinez-Torres F; Zou W; Krisko JF; Fleming E; Zein S; Powell DA; Wahl A; Kwak YT; Welch BD; Kay MS; Payne DA; Gallay P; Appella E; Estes JD; Lu M; Garcia JV
    J Virol; 2011 Aug; 85(15):7582-93. PubMed ID: 21593172
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety Assessment of Microbicide 2P23 on the Rectal and Vaginal Microbiota and Its Antiviral Activity on HIV Infection.
    Gao Z; Fu R; Li X; Wang J; He Y
    Front Immunol; 2021; 12():702172. PubMed ID: 34447373
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reformulated tenofovir gel for use as a dual compartment microbicide.
    Dezzutti CS; Rohan LC; Wang L; Uranker K; Shetler C; Cost M; Lynam JD; Friend D
    J Antimicrob Chemother; 2012 Sep; 67(9):2139-42. PubMed ID: 22581908
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A quantitative multiplex nuclease protection assay reveals immunotoxicity gene expression profiles in the rabbit model for vaginal drug safety evaluation.
    Fichorova RN; Mendonca K; Yamamoto HS; Murray R; Chandra N; Doncel GF
    Toxicol Appl Pharmacol; 2015 Jun; 285(3):198-206. PubMed ID: 25818602
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety of a nonoxynol-9 vaginal gel in Kenyan prostitutes. A randomized clinical trial.
    Martin HL; Stevens CE; Richardson BA; Rugamba D; Nyange PM; Mandaliya K; Ndinya-Achola J; Kreiss JK
    Sex Transm Dis; 1997 May; 24(5):279-83. PubMed ID: 9153737
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multicompartmental pharmacokinetic model of tenofovir delivery by a vaginal gel.
    Gao Y; Katz DF
    PLoS One; 2013; 8(9):e74404. PubMed ID: 24040241
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Topical microbicides for preventing sexually transmitted infections.
    Obiero J; Ogongo P; Mwethera PG; Wiysonge CS
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD007961. PubMed ID: 33719075
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Single-dose pharmacokinetics of tenofovir alafenamide and its active metabolite in the mucosal tissues.
    Cottrell ML; Garrett KL; Prince HMA; Sykes C; Schauer A; Emerson CW; Peery A; Rooney JF; McCallister S; Gay C; Kashuba ADM
    J Antimicrob Chemother; 2017 Jun; 72(6):1731-1740. PubMed ID: 28369415
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    Hijazi K; Iannelli F; Cuppone AM; Desjardins D; Caldwell A; Dereuddre-Bosquet N; Scala C; Smith KA; Mukhopadya I; Frank B; Gwozdz G; Santoro F; Grand RL; Pozzi G; Kelly C
    Mol Pharm; 2020 Mar; 17(3):852-864. PubMed ID: 32017579
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A multi-compartment, single and multiple dose pharmacokinetic study of the vaginal candidate microbicide 1% tenofovir gel.
    Schwartz JL; Rountree W; Kashuba AD; Brache V; Creinin MD; Poindexter A; Kearney BP
    PLoS One; 2011; 6(10):e25974. PubMed ID: 22039430
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety study of nonoxynol-9 as a vaginal microbicide: evidence of adverse effects.
    Stafford MK; Ward H; Flanagan A; Rosenstein IJ; Taylor-Robinson D; Smith JR; Weber J; Kitchen VS
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Apr; 17(4):327-31. PubMed ID: 9525433
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design and in vitro evaluation of tenofovir-loaded vaginal gels for the prevention of HIV infections.
    Timur SS; Şahin A; Aytekin E; Öztürk N; Polat KH; Tezel N; Gürsoy RN; Çalış S
    Pharm Dev Technol; 2018 Mar; 23(3):301-310. PubMed ID: 28503983
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mucosal integrity and inflammatory markers in the female lower genital tract as potential screening tools for vaginal microbicides.
    Su HI; Schreiber CA; Fay C; Parry S; Elovitz MA; Zhang J; Shaunik A; Barnhart K
    Contraception; 2011 Nov; 84(5):525-32. PubMed ID: 22018129
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Full depth measurement of tenofovir transport in rectal mucosa using confocal Raman spectroscopy and optical coherence tomography.
    Presnell AL; Chuchuen O; Simons MG; Maher JR; Katz DF
    Drug Deliv Transl Res; 2018 Jun; 8(3):843-852. PubMed ID: 29468424
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nonoxynol-9 100 mg gel: multi-site safety study from sub-Saharan Africa.
    Hoffman IF; Taha TE; Padian NS; Kelly CW; Welch JD; Martinson FE; Kumwenda NI; Rosenberg ZF; Chilongozi DA; Brown JM; Chirenje M; Richardson BA
    AIDS; 2004 Nov; 18(16):2191-5. PubMed ID: 15577653
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of a combination microbicide gel formulation containing IQP-0528 and tenofovir for the prevention of HIV infection.
    Ham AS; Ugaonkar SR; Shi L; Buckheit KW; Lakougna H; Nagaraja U; Gwozdz G; Goldman L; Kiser PF; Buckheit RW
    J Pharm Sci; 2012 Apr; 101(4):1423-35. PubMed ID: 22227864
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High levels of adherence to a rectal microbicide gel and to oral Pre-Exposure Prophylaxis (PrEP) achieved in MTN-017 among men who have sex with men (MSM) and transgender women.
    Carballo-Diéguez A; Balán IC; Brown W; Giguere R; Dolezal C; Leu CS; Marzinke MA; Hendrix CW; Piper JM; Richardson BA; Grossman C; Johnson S; Gomez K; Horn S; Kunjara Na Ayudhya RP; Patterson K; Jacobson C; Bekker LG; Chariyalertsak S; Chitwarakorn A; Gonzales P; Holtz TH; Liu A; Mayer KH; Zorrilla C; Lama J; McGowan I; Cranston RD
    PLoS One; 2017; 12(7):e0181607. PubMed ID: 28750059
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preference of Oral Tenofovir Disoproxil Fumarate/Emtricitabine Versus Rectal Tenofovir Reduced-Glycerin 1% Gel Regimens for HIV Prevention Among Cisgender Men and Transgender Women Who Engage in Receptive Anal Intercourse with Men.
    Carballo-Diéguez A; Giguere R; Dolezal C; Leu CS; Balán IC; Brown W; Rael C; Richardson BA; Piper JM; Bekker LG; Chariyalertsak S; Chitwarakorn A; Gonzales P; Holtz TH; Liu A; Mayer KH; Zorrilla CD; Lama JR; McGowan I; Cranston RD;
    AIDS Behav; 2017 Dec; 21(12):3336-3345. PubMed ID: 29119473
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Project Gel a Randomized Rectal Microbicide Safety and Acceptability Study in Young Men and Transgender Women.
    McGowan I; Cranston RD; Mayer KH; Febo I; Duffill K; Siegel A; Engstrom JC; Nikiforov A; Park SY; Brand RM; Jacobson C; Giguere R; Dolezal C; Frasca T; Leu CS; Schwartz JL; Carballo-Diéguez A
    PLoS One; 2016; 11(6):e0158310. PubMed ID: 27362788
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.